larg cap sector weight market weight
modest long-term grower averag valuat feel fairli valu
kra hope biggest potenti rest combo earli
tezepelmab could deliv dream asthma
report limit sole use client wolf research pleas refer disclosur section locat end report analyst certif
disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
tabl content
initi peer perform rate
summari view modest long-term grower averag valuat tough see
out-performance come unless pipelin drug deliv alreadi expect
initi peer perform rate reason grower long-term still
averag rel larg cap biopharma biotech big pharma name cover organ financi
perform would quit modest otezla acquisit provid boost given amgn current
valuat middl pack price-to-earnings multipl basi hard see drive out-performance unless
upcom pipelin read-out yield alreadi expect
two tangibl pipelin asset tezepelumab
cancer excit industri begun crack code elus kra cancer
pathway confid high monotherapi viabl rather combin therapi like best
path forward moment
tezepelumab asthma enter crowd space asthma biolof captur split econom
howev could deliv dream efficaci regardless eosinophil level per data btd statu
omecamtiv mecarbil heart failur one wildcard even approv quit possibl nich size
biosimilar hurt help simultan collect matur brand biolog
product face steadi biosimilar competit effect seller biosimilar
model latter add increment revenu that good hard model biosimilar
confid price possibl futur interchang add risk revenu stream
price target current price
reli price-to-earnings multipl ep vs peer group averag rang
impli price-to-earnings multipl ep vs peer group averag rang
dcf analysi inform basi price target calcul cover name yield fair valu
ltm boost enbrel patent win kra otezla acquisit bgne collab
ytd stock gener move market covid turmoil
next major multi-tumor drug
progress final made target ever-
elus kra pathway span sever differ
tumor may competitor
lead analyst estim could low
tezepelumab deliv eosinophilic-agnost
regardless eosinophil level big differenti
best biosimilar seller posit
capit billion dollar worth
innov biolog go patent come
year hedg risk
stabl base layer
deal boost growth otezla good exampl
afford plenti dri
upcom kra data could disappoint least
monotherapi durat respons wane
quick could take bloom rose
head vs otezla poetyk trial clean
beat could impair otezla growth outlook
asset bought
stori lack excit big slow
move late-stag pipelin may
deliv investor hope
need
gener eros amgn base could
surpris downsid lot disappear
revenu stream start point amgn
oper margin high best stay flat
quit possibl go long period slow
contract thu willing pay
otezla
wolf research estim analysi
catalyst bigger one
kra cancer
import one
monotherapi late-lin lung pdx combo
keytruda combo mek combo tumor
tezepelumab tslp allerg condit
top-line asthma data navig
top-line data advanc psoriasi patient milder diseas
top-line data galactic-hf
radar screen investor
pipelin snapshot time news what model
assettarget wr estimatesnext like import event tezepelumabtslpinflammatori pathfind data asthma top-line data atop dermat cours data copd codebreak initi data codebreak initi data mecarbilmyosinheart galact hf data base revenu vs peer big biotech pharma
base revenu analysi look product market today
 assum futur pipelin drug fail measur durabl
look averag medium term denosumab loe
outlook index
outlook index
unlik last slide show total revenu base pipelin assumpt
come year coupl medium level pipelin drug
contribut make look like big pharma
outlook index
outlook index
revenu diversif across cover biotech name mean
compar less singl product concentr risk other
use compani model assum
certain rate return spend
yield futur pipelin product
specif cant known today
divid rev innov vs biosimilar
innov product contribut increment revenu
biosimilar contribut increment revenu
matter biosimilar harder forecast long-term
neulasta neulasta face on-going biosimilar eros novn although may
reason think product could long tail slide
esa franchis biosimilar epoetin pressur aranesp ckd set epogen expect asp pressur
potenti remov product contract expiri anoth consider azn/fgen roxadustat slide
aimovig like leverag first-mov posit maintain volum growth go forward
on-going payer access issu like curtail revenu potenti slide
repatha continu run ahead lower price growth pick unclear
novartis/mdco inclisiran may impact slide
kyproli consist grower get use mm academ center mostli gain covet
nplate think goe ex-growth come year coincid loe market leader promacta
dopetelet launch upsid gain chemotherapy-induc thrombocytopenia indic slide
prolia prolia continu enjoy growth denosumab loe eu given best-in-
class profil among anti-resorpt efficaci adher standpoint slide
even new kid block osteoporosi excit initi high given dual mechan
bone remodel howev anabol agent carri baggag usual limit durat use slide
enbrel follow favor district court decis august enbrel stori littl bore
compar good way longer growth brand loe slide
otezla continu growth easi see decent oral agent growth opportun ahead product also
gain indic mild patient bewar competit head-to-head trial vs otezla slide
vectibix vectibix growth constrain limit label rel erbitux uncertainti biosimilar time
xgeva newer mm label continu drive near-term growth potenti upsid china bgne loe
far away anoth denosumab product prolia eu slide
parsabiv remov add-on payment may pressur asp think long-term volum
grow given potenti superior outcom vs oral calcimimet slide
biosimilar execut fastest biosimilar launch us date lever
experi brand oncology/biolog expect continu futur launch slide
tezepelumab asthma major event pathfind data
tezepelumab anti-tslp mab partner azn sever asthma besid offer novel mechan
action phase data support possibl product work sever asthmat regardless
eosinophil level holi grail sort among contemporari biolog failur replic result
question howev happen san/regn dupix beyond asthma tezepelumab phase
trial atop dermat alreadi fail copd seem long-shot indic
neither near-term rate slide
cancer high profil cancer drug hit often describ
undrugg target kra pathway go popul kra mutant tumor
potenti registr codebreak monotherapi data due year prospect monotherapi
arent great due kra escap mechan combin agent like imper
commerci opportun pressur number competitor space
direct inhibitor other tangenti boehringer-ingelheim trov slide
omecamtiv mecarbil heart failur follow cosmic-hf data
galactic-hf pass two interim analys reason odd success coin toss read-
occur howev even product cross regulatori hurdl still defin
popul drug would see usag given increas avail hf agent like omecamtiv
may mid-siz sub peak product slide
revenu ep estim vs consensu
broadli in-lin consensu
beyond hard know analyst model dont go far
comp sheet cover compani biotech pharma
excl upjohn azn w/o us/eu europ pharmaeu target multipl price-to-earnings-to-growth analysi
look in-lin rel peer near medium-term
use rel valuat methodolog determin price target use target price-to-earnings
multipl appli forward ep
target multipl primarili take account pipelin option binari event risk near- long-term
pt repres target multipl ep current
trade ep
rang target multipl use cover compani span
also show dcf calcul use determin pt
share dcf valu equitynpv cash flow termin valu per stock amgn-bgn deal
turn-key expans amgn presenc china
like acceler clinic trial timelin china
octob bgne announc partnership focus
oncolog portfolio china
still go alon non-oncolog diseas area china prolia
deal structur includ commerci compon
commerci bgne commerci split profit xgeva kyproli
blincyto china year certain right revert
 bgne co-fund develop pipelin
compound bgne contribut toward goal
leverag bgne oncolog network china
pay ex-china royalti futur sale product except
part agreement acquir bgne stock
book cut bgne profit equiti account method
differ mix tumor type china gastric cancer among five
preval
lung cancer number incid case china us
given larger size cancer incid popul china less advanc
treatment option oncolog trial enrol rapidli us faster
leverag bgne clinic platform may abl meaning
acceler clinic timelin get market first ahead competitor
chines approv open access new lung cancer patient potenti
kra new patient kra annual
asthma eosinophilic-agnost data translat
result late
copd holi grail asthma biolog
long-shot read
studi fail read
anti-tslp therapi partner azn develop number atop
condit asthma copd atop derm
thymic stromal lymphopoietin tslp cytokin primarili express epitheli
tissu kick inflammatori cascad
current azn control asthma/copd develop atop dermat
econom almost split azn get slightli
event phase navig asthma data late
model vs consensu
feel ahead navigator/sourc asthma data
teze show encourag asthma exacerb data consist across
replic
one good sign fda breakthrough therapi design low eo
howev dont forget dupix experi also encourag fell short
best guess odd drug show benefit subgroup take share
competitor sever also grow market
tezepelumab asthma program similar regn dupix program
program sever asthma oral corticosterioid oc -depend asthma
trial tri show efficaci eosinophilic-agnost set
given upstream posit tslp rel dupi act biolog
make sens teze could dampen broader spectrum inflammatori mechan
path-hom studi teze autoinjector form like acceler
commerci uptak base experi
navig basi asthma regulatori file
trialpopulationphaseenrollmentendpointpcdnavigatoradult adolesc sever adolesc sever usag metricsjul daili oc usesep sever inflammatori cell countjan sever tezepelumab look competit versu incumb
exacerb rate reduct across sever asthma spectrum safeti benign
note howev risk reduct vs placebo similar dupix phase ii
caveat data apples-to-orang teze data set
lower better
tezepelumab efficaci consist across subgroup
teze consist robust effect exacerb across subgroup
includ blood eo count low feno level low statu eosinophil
ige render patient larg neutrophil phenotyp
histori say cautiou data see next slide
dont forget dupix experi
dupix trial asthma patient also appear benefit regardless
howev confirm find yet dupix still competit product
rais question whether teze could suffer fate
one encourag sign covet fda breakthrough therapi design
low-eo subtyp dupi never
tezepelumab copd worthi pursuit long shot
juli azn/amgn initi poc studi tezepelumab copd
regardless phenotyp
copd un-cross hurdl asthma biolog given
heterogen inflammatori profil mix involv
teze appear block upstream interleukin upregul
exacerb role activ dendrit cell mayb
help deliv good
current approv copd therapi modestly-effect old school inhal
mean signific unmet need patient inadequ control
azn/amgn wont data near-term driver
tezepelumab atop derm fail lead new
tezepelumab fail first phase atop dermat trial
specif teze fail demonstr superior
amgn/azn incorpor learn trial new phase studi
result
background part
week timepoint stringent
arms-placebo-tezepelumab mg-placebo-tezepelumab low dose medium dose high dose criteria-moder sever ad-ad bodi area-easi bodi ad least two years-cess background therapi part primari iga weekssecondari chang easi iga respons scorad chang scorad nr pruriti time scorad pruritu nr pk profil immunolog
enbrel energ bunni w/ low batteri
otezla bmi take
big profit fanchis net basi declin
enbrel face steadi slow declin due new competit price pressur
otezla grow slowli due increas competit price pressur
advanc studi milder psoriasi help
assum bmi work mean show better efficaci otezla
enbrel etanercept tnfi fusion protein came acquisit
immunexamgn market product north america
favor district court decis took away fear earli gener
major relief still slow declin
launch us happi birthday eu gener launch
high brand awar loyalti
evidenc still sell us
sandoz appeal lower court rule
lot newer product chip away
variou indic en rout
otezla apremilast inhibitor acquir celg healthi
ftc mandat divestitur
current approv three indic moderate-to-sever plaqu psoriasi psoriat
arthriti ulcer associ behcet
launch
model forecast sale peak
first-mov advantag oral psoriasi
efficaci competit vs biolog
moderate-to-sever set
toler easi give
oral program otezla
expans mild-to-moder pso
under-penetr intern market
compar arm result
payor dynam set heat new
otezla psoriasi weakerbut oral safe easier give
compar biolog otezla efficaci gener less competit
valu proposit rest mostli oral dose plu weight loss pt
otezla bmi crosshair
develop novel oral inhibitor treatment moderate-to-sever
phase trial show clearanc data close biolog side side comparison
concern mild acn neg differenti
phase poetyk-pso head-to-head trial read placebo otezla
side-by-sid comparison otezla
otezla advanc trial could open new patient segment
on-going advanc trial mild-to-moder pso could key new growth
opportun otezla mild patient constitut major psoriat
safeti bar high mild diseas otezla safe
also mild patient treat exist option topic
readout expect difficult handicap odd risk reward skew
posit stock perspect given size opportun
vectibix steadi biosimilar
xgeva matur brand face loe
initi excit kra cool
contextu kra data date
mirati data stack codebreak
combo like path forward
vectibix grow assum biosimilar competit arriv arbitrari
assumpt oddli biosimilar develop yet egfr mab
xgeva continu grow european loe also given lack
hesitantli includ revenu forecast model highlight
caution given earli natur data clear monotherapi viabl
combin therapi could higher odd success yet data
vectibix panitumumab anti-egfr antibodi indic monotherapi wtkra
mcrc fail folfiri
loe eu us assum biosimilar arriv oddli biosimilar
yet activ develop
model vs consensu
one two anti-egfr mab
label broad erbitux
differ igg backbon less
immun prime rel erbitux
uncertainti biosimilar
eventu show lli erbitux
situat biosim
xgeva amgn denosumab sister product osteoporosi drug prolia
anti-rankl antibodi indic skelet event reduct malign tumor set
also hypercalcemia malign hcm
xgeva part amgn china collabor bgne
model vs consensu
multipl myeloma help
loe approach outlin
sustain growth matur brand
appear innov pipelin
product xgeva indic
entri china bgne
coval kra inhibitor treatment cancer driver
mutat tumor
kra oncogen play role cell signal prolifer
mutat neg signal disrupt caus uncontrol prolifer
kra mutat often found pancreat colorect
lung cancer
histor undrugg target
event nsclc monotherapi data earli data
model consensu includ rev hesit
feel ahead codebreak
phase dose escal data immatur orr mg meet
regulatori threshold durabl remain outstand question real uncertainti
even approv transient benefit would like constrain commerci opportun
krasi probabl find home combin
watch codebreak
monotherapi pdx combo kra solid tumor
esmo mg data orr nsclc orr
potenti pivot lung mono data like need mo
dor registr
combo studi kra solid tumor
enrol cohort
meki orr kra nsclc typic rang
could tamp resist mechan
earli pdx combo data
monotherapi target nsclc set
compar monotherapi docetaxel
retrospect analys kra patient
mpf month mo month chemo
street expect high low right
share price heavili lever kra excit news flow
beg question expect high low right
first in-human data late may
 first respons call juli
 nsclc data present wclc sept
addit data present esmo late sept
earli nsclc data encourag durabl short
dose-escal grand total produc partial respons
high rate diseas control nsclc benefit transient
highest dose orr partial diseas control
median durat treatment week patient still treatment
addit patient activ came wclc happen often
oncolog much emphasi earli data run risk disappoint later
fakih et al phase studi novel
inhibitor advanc solid tumor kra mutat present
data show signalbut excit
also dose-escal one patient partial respons
stabl diseas experienc tumor shrinkag
median durat stabl diseas week
compar stivarga lonsurf month
biomark support efficaci rapid declin ca
seen dose low mg
fakih et al phase studi novel
inhibitor advanc solid tumor kra mutat present
futur like rest w/combin
mtor-medi bypass signal prompt concern around singl agent
alreadi reflect short dor poor depth respons
combin regimen target kra plu either upstream mechan like
downstream like show pre-clin synergi
combo like necessari off-set product addit kra protein
codebreak enrol mek combo like expand
moa
hallin et al insight toward therapeut suscept kra
small molecul inhibitor present confer
kra mutat strongli associ increas express unlik
driver mutat
kra mutat upregul express p-erk pathway
could provid addit target combo futur
see synergist potenti could halt tumorigenesi pdx inhibit may
acceler clearanc exist tumor cell
howev keytruda monotherapi set high bar orr kra
nsclc popul per recent patient data set
mirati look compar efficaci
look high-dos nsclc data appear similar
efficaci profil similar orr diseas control rate small data set
respond increas tumor shrinkag subsequ scan may
posit implic durat respons
taken togeth appendic tumor data see reason
conclud one drug activ
undifferenti profil could favor
first mover
compani commerci know-how oncolog
compani present
kyproli mostli confin relapsed/refractori set
blincyto small steadi watch nv
nplate potenti upsid chemotherapy-induc
assum kyproli stay limit primarili relapsed/refractori studi
continu smolder mm trial underway
nplate could see upsid chemotherapi induc thrombocytopenia
model
kyproli break r/r set
kyproli carfilzomib infus proteasom inhibitor often use backbon
r/r multipl myeloma mm effect respect drug
clarion trial fail indic expans studi well
indic continu usag alreadi occur despit
acquisiton onyx
launch eu loe us
model vs consensu
new combo daratumumab
mm crowd categori overal lot
trial continu registr enabl
per se difficult imagin superior profil
gener bortezomib
upsid potenti smolder myeloma
approv therapi exist small trial
view good risk reward
novel agent develop drug-bas
cell-bas
offset volum gain mean clear
superior need displac
potenti ip risk manufactur patent
clarion compar kmp vmp transplant-elig mm big zero hr
clarion failur number addit trial run investig
initi optim combo backbon
registr enabl per could still help convinc doc
use center alreadi
trialsponsorphaseenrollmentregimenpcdcommentscobraunivers trial versu trial versu velcadedsmm xviiwuerzburg univers e-krd medikamentoes kyproli monotherapi kyproli selinexor combo kyproli opportun smolder myeloma would nice
smolder myeloma smm consid pre-cancer precursor
smolder pt progress full-blown mm w/in
fda-approv treatment today treatment paradigm watch
smolder repres multipl myeloma case
current number smaller often investigator-initi trial
kyproli set includ
phase ascent combo revlimid darzalex
dexamethason schedul read
phase istopmm combo revlimid dexamethason data
drug also continu studi smm incl daratumumab
earli data gem-cesar cur trial high-risk smm present
encourag signal tabl
deepen respons time scr mrd neg
relaps rate zero clinic progress
os follow-up
safeti profil in-lin krd activ myeloma
matur data need determin whether krd asct effect respons data
suggest advantag daratumumab mono centauru trial
wolf research mateo mv et al cur strategi high-risk
smolder myeloma gem-cesar carfilzomib lenalidomid dexamethason
krd induct follow hdt-asct consolid krd mainten
rd present
smolder myeloma remain remiss
respons categoryinduct asct blincyto overview
blincyto blinatumomab amgn first bite molecul approv come
indic mrd remiss r/r
launch
util consolid set help
skirt near-term competit
four week continu iv infus
oner tie high rate port site
dlbcl b-cell malign
blincyto fare car-t product
enter space
develop hle half life
extend form reinforc
blincyto potenti risk novarti oberon trial w/kymriah
novn current run phase trial adult compar kymriah
car-t blincyto besponsa
data although interim data cut like
could downsid novn success
usual inconveni car-t administr like less materi
clear blincyto safeti better base incid seen
bite platform product gener
pediatr complet remiss rate durat respons favor
kymriah compar pivot blincyto data
nplate romiplostim thrombopoietin receptor agonist tpo-ra approv
thrombocytopenia patient immun thrombocytopen purpura itp
consensu model nplate go ex-growth come year promacta loe
launch anoth oral doptelet
howev work extend nplate revenu initi phase
trial platinum-bas chemo nsclc ovarian breast recit
trial folfox
model vs consensu
offer larg upsid potenti nplate
promacta loe pressur nplate
indic promacta
volum price
nplate differenti doptelet
doptelet could outperform nplate
promacta sc dose
dose inconveni
nplate data encourag on-going
investigator-initi trial pt interrupt chemotherapi due
patient platelet count rebound allow resumpt chemotherapi
durabl effect patient experienc breakthrough thrombocytopenia
requir dose reduct delay
potenti valu clear patient abl complet full cours cancer
larg greenfield market opportun
risk
neulasta rev hit hardest
neulasta channel durabl
neulasta revenu continu declin biosimilar pressur model eros
steadi rate step-chang function
eros temper somewhat due price dynam larg oncolog gpo
onpro formul provid partial off-set well
approv patent expir
still amgn biggest product total revenu
formul switch onpro neulasta sale start top
model vs consensu
onpro could protect volum pre-
passthrough statu biosimilar drive
revenu zero
clinic hospit could
novn biosimilar may fail
gener traction
addit biosimilar drive increment
neulasta sale provid
hospit margin
pressur combin
awp reimburs
commerci plan
reimburs view
channel easiest
sourc volum loss
neulasta
reimburs across payer
onpro
view hospit low-hang fruit biosimilar adopt given
udenyca coheru pass-through statu reimburs udenyca asp
neulasta asp vs neulasta
attract institut revenu profit perspect
drive biosimilar uptak
neulasta hospit unlik total loss
hospit outpati reimburs typic base awp percent charg
total cover live percentag charg claim less like
unprofit view given hospit set charg claim averag
commerci hospit outpati asp
commerci hospit revenu could rel
durabl see payer forc biosimilar util cut reimburs cost
neulasta onpro formul help stem declin
onpro on-bodi injector like patch deliv drug home
despit medic necessari major neulasta patient
conveni yield onpro prevent next-day visit inject protect
volum extent
brand
contract expir impact
parsabiv inclus esrd bundl drag
continu asp pressur epogen contract culmin loss
prefer statu
aranesp revenu pressur especi dialysi hospit ckd set
retacrit
parsabiv revenu neg impact expiri add-on payment
one-tim impact
parsabiv continu grow volum on-going loe sensipar base
higher efficaci bar potenti improv real-world outcom
aranesp approv us loe biosimilar epogen pressur sale
market epogen ckd dialysi anemia set market chemo
non-dialysi anemia set
market aranesp across set
possibl end renew
expir contract
aranesp could remain resili
new competit come
like
epogen aranesp market leader among esa gener wac sale
thank larg dialysi provid contract epogen
asp pressur distort net sale pictur howev
epogen quickli could davita-rel revenu slide
follow expiri freseniu suppli agreement epogen volum
declin follow month
could experi someth similar switch biosimilar
volum declin freseniu switch mircera
amplifi lower net price
epogen/aranesp competit azn/fgen roxadustat
azn develop roxadustat oral hif-ph inhibitor anemia
associ ckd pdufa set
first hif-ph last
akebia vadadustat
gsk daprodustat
announc posit top-line data phase olympu
rocki trial ckd anemia decemb
azn/fgen enrol phase ii program chemotherapy-induc anemia set
competit aranesp oncolog set
difficult know treat roxadustat approv ensur placement
medicar part repres overhang amgn esa franchis
treat patient roxadustat could creat excess profit provid
shift cost creat econom incent use roxadustat
calcimimet approv manag secondari hyperparathyroid
shpt dialysi patient
approv patent expiri
grow steadili sale y/i reach
first intraven formul calcimimet parsabiv place
transit period dialysi center receiv increment payment fulli
esrd bundl
commerci advantag even though
label
expiri add-on payment may
prevent util dialysi center
uncertainti around fate gener
sensipar challeng launch
outcom ckd patient
poor econom esrd product mean
competit pipelin limit
parsabiv data may protect sensipar gener
phase head-to-head trial amgn oral sensipar parsabiv
achiev non-inferior number patient achiev reduct pth
also reach stat sig superior sensipar secondari endpoint
data label howev limit amgn abil market doc
real-world outcom may favor parsabiv given poor adher rate sensipar
tie high pill burden
sensipar on-going at-risk gener competit
repatha like maintain lead posit
omecamtiv mecarbil hard call ahead
reluctantli includ model
repatha continu lead market especi us praluent revert
omecamtiv includ model hesit probabl nich heart failur
inject inhibitor lipid manag
approv loe
follow slow start final gain traction class lower price help
model sale peak
lipid market larg class
new ndc medicar neg
penetr remain low
seem invest less behind
praluent leav lead
vesalius-cv could expand patient
impact price product margin
possibl competit threat novarti
inclisiran mdco acquisit novn
much greater cv know-how could
novn disrupt price
repatha fourier vs odyssey matter
fourier odyssey cardiovascular outcom trial cvot
mace also caus mortal
design differ fourier use endpoint shorter follow-up
matter nah doc view drug essenti
valid approach
present aha
outcomesdeath/mi/ischem coronari outcomesdeath/mi/ischem coronari repatha vesalius-cv could broaden label
march announc initi vesalius-cv new patient
focus high-risk cardiovascular diseas cvd patient never
experienc mi stroke
could expand repatha target popul million patient top
elig current label
posit vesalius-cv data would help repatha keep ahead competit
expect read may ahead novarti inclisiran cvot data dec
inclisiran novarti formerli mdco sirna
main differenti inject dose vs everi week
file approv occur us y/e
reduct appear competit base
novarti manag paint pictur inclisiran almost like vaccin term
give broadli infrequ prevent heart attack
initi ramp seem destin slow
inclisiran definit long-term outcom data read
howev could novarti disrupt price launch effort drive
immedi paradigm shift would downsid
omecamtiv mecarbil cardiac myosin activ
treatment heart failur reduc eject fraction hfref
cardiac myosin respons gener forc power stroke
mechan follow atp hydrolysi drive cardiac contract
event galactic-hf data full data
model vs consensu includ hesit
feel ahead galactic-hf
complet novel moa like hf automat creat element risk
elev troponin signal cosmic potenti worrisom sign address
care dose titrat suggest narrow therapeut index
galact trial pass interim analys protocol chang
kol uncertain moa impact systole/diastol translat also concern
hypotens
improv soc rais bar entresto soon azn
overal read-out feel like coin toss even posit question
fit whether nich sever patient
prolia steadi goe
even limit safeti least us
prolia continu grow loe despit larg gener anti-resorpt
model standard biosimilar eros loe note present one
biosimilar clinic sandoz
even hit blockbust size eventu anabol agent remain limit
scope one also worrisom black warn us
patient primarili receiv anabol agent failur anti-resorpt agent
use first line restor normal bone structur switch mainten
therapi anti-resorpt
slow rate
drive increas
prolia amgn denosumab sister product xjeva anti-rankl antibodi
indic variou form osteoporosi women men
differenti anti-resorpt agent inhibit osteoclast directli
also indirectli inhibit matur osteoclast lineag cell
matur drug yet still grow healthi clip
model vs consensu
prolia differenti dose
lot gener choic old
schedul clean safeti profil
efficaci across major bone remodel
fosamax other
label extens efficaci
biosimilar develop beyond
sandoz multipli number
prolia well generic space
normal expens biolog annual wac
prolia dose may boost adher vs anti-resorpt agent
variabl dose schedul often dose restrict fast
lte pivot freedom studi prolia improv bmd
seem plateau spine hip wherea older agent typic
small head-to-head studi prolia better efficaci anti-resorpt
even romosozumab amgn anti-sclerostin antibodi develop collabor
ucb commerci ex-europ
sclerostin two thing upregul osteoclast-medi resorpt
model vs consensu
differenti mechan hit
mix signal efficaci safeti
frame trial
post-market data could get doc
comfort cv profil
seem us concern
transderm patch tymlo could
squeez even forteo
cgrp inhibitor fill unmet need
predict seen payer resist
first-mov advantag lot
competit exist come
smart contract caremark aimovig like remain market leader
inject cgrp space
expans primari care set continu slowli sure
new competitor formul help grow market destroy aimovig includ
vylepti iv lundbeck atogep oral agn/abbv rimegep
oral
give credit synergist combo follow demis amgn
subcutan cgrp inhibitor approv migrain prevent treatment
erenumab calcitonin gene-rel peptid cgrp neuropeptid
releas caus inflamm headach pain
approv loe
partnership novn us commerci right
forecast
oral cgrp prepar enter pivot
trial migrain prophylaxi
enjoy first mover statu biolog
migrain cgrp space broadli
drug target cgrp receptor
posit liberti data reflect
head-to-head trial vs incumb
bill advantag
lli emgal broader/bett label
respons rate treatment
aimovig quick rundown current cgrp space
indic cm em
coverag across
liberti data
indic cm em
ech
indic cm em
prefer statu one
coverag par
offer monthli
singl monthli dose
reaction label
free data label
ajovi patient receiv
quarterli dose skew apples-
aimovig long-term commerci success hing access
three compani launch product gener sampl free drug
program provid year free drug new patient rais concern
abil convert free drug paid script
aimovig sale growth show convers happen
pole posit rel teva
aimovig lundbeck intraven threat
lundbeck recent receiv approv
vyepti intraven cgrp peptide-
target antibodi chronic episod
efficaci data em compel
although differ
subcutan cgrp absolut
chronic data howev
impress absolut basi
buy bill mechan
part appeal doc think
popul repres minor
aimovig oral cgrpsan existenti threat could
current allergan biohaven develop atogep
rimegep oral cgrp migrain prophylaxi
phase iib atogep gener reduct mean headach day
appear larg similar subq agent gener phase
atogep ph data slate could overhang
injectablesbut odd manag doesnt talk much
small molecul oral off-target safeti issu vs target biolog
gepant shown sign liver tox past
best-in-class portfolio lucr opportun
take biolog compani market biosimilar
continu lead biosimilar develop know develop
brand biolog help develop complex biosimilar product
continu lead biosimilar commerci tradit gener
manufactur less commerci know-how continu struggl
seismic chang biosimilar landscap
interchang rule chang could disrupt
assum royalti rate partner acquir watson
target number high valu biolog
target seven valuabl near-term biosimilar opportun
mani case first-mov advantag least us
commerci biosimilar busi build amgn commerci expertis
infrastructur biolog target therapeut area provid
long-held view best seller biosimilar drug
innov biopharma compani rel gener compani
goodwil among regul prescrib patient
biosimilarbrandmoleculeu statuseu statusnext stepsamjevitahumiraadalimumabapprovedlaunchedlaunch us januari litig follow at-risk launchmvasiavastinbevacizumablaunchedapprovedcontinu litig follow at-risk launchavsolaremicadeinfliximabapprovedfiledprepar launch us await decis euabp nhl data handabp pnh data phase phase us mvasi kanjinti launch steadi progress
follow amgn at-risk launch juli gain
avastin herceptin market respect
addit entrant come may benefit first-mov advantag
yet certain partli depend respond price competit
presum late entrant presum foster
mvasi kanjinti biosimilar
pole posit us humira build enbrel
us humira biosimilar crowd first six month
market exclus
potenti downsid risk commerci opportun boehring
ingelheim bi run interchang studi would assum
fda end allow interchang specif pharmacy-count substitut bi
succe other would follow suit would faster race bottom
fda previous suggest open concept substitut
incom statement oper incom expens outstand margin total profit profit profit incom growth oper balanc sheet statement
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ lt debt leas treasuri flow financ activ increas decreas cash sheet cash equival st properti plant goodwil current term non-curr comprehens sharehold liabil sharehold disclosur section analyst certif analyst wolf research llc primarili respons research report whose name appear first front page research report herebi certifi recommend opinion express research report accur reflect research analyst person view subject secur issuer ii part research analyst compens directli indirectli relat specif recommend view contain report import disclosur price chart rate price histori note op outperform pp peer perform under-perform wolf research llc fundament valuat methodolog compani fundament valuat methodolog price-to-earnings target multipl forward ep estim wolf research llc fundament recommend rate price risk compani risk may imped achiev recommend rate price upsid risk pt omecamtiv gener profil competit entresto farxiga demonstr durabl monotherapi respons lcm legaci product nplate deliv materi upsid downsid risk pt pivot trial readout teze omecamtiv neg growth product like aimovig repatha cede market leadership newer product otezla blown bmi poetyk trial appeal court revers favor decis enbrel wolf research llc research disclosur compani research disclosur none disclosur wolf research llc fundament stock rate outperform op secur project outperform analyst industri coverag univers next month peer perform pp secur project perform approxim line analyst industri coverag univers next month under-perform secur project under-perform analyst industri coverag univers next month wolf research llc use rel rate system use term outperform peer perform under-perform see definit pleas care read definit rate use wolf research llc research addit sinc wolf research llc research contain complet inform concern analyst view pleas care read wolf research llc research entireti infer content rate alon case rate research use reli upon invest advic invest decis base upon individu circumst consider wolf research llc sector weight market overweight mo expect industri outperform primari market index region least next month market weight mw expect industri perform approxim line primari market index region next month market underweight mu expect industri under-perform primari market index region least next month wolf research llc distribut fundament stock rate march outperform invest bank client peer perform invest bank client under-perform invest bank client wolf research llc assign rate buy hold sell stock cover outperform peer perform under-perform respect equival buy hold sell repres rel weight defin satisfi regulatori requir outperform design correspond buy peer perform design correspond hold under-perform design correspond sell wolf research secur wolf research llc adopt use wolf research brand name wolf research secur member finra www finra org broker-deal affili wolf research llc respons content materi analyst publish report dualli employ wolf research llc wolf research secur content report use sole inform purpos regard offer solicit offer buy sell secur financi instrument servic discuss herein opinion commun constitut current judgment author date time report subject chang without notic inform herein believ reliabl wolf research affili includ limit wolf research secur make represent complet accur inform provid commun design replac recipi decision-mak process assess propos transact invest involv financi instrument discuss herein recipi encourag seek financi advic financi advisor regard appropri invest secur financi instrument refer report understand statement regard futur perform financi instrument secur referenc herein may realiz past perform indic futur result report intend distribut use person entiti locat distribut use would contrari applic law would subject wolf research llc affili registr requir within locat addit import disclosur pleas see www wolferesearch com/disclosur view express wolf research llc research report regard sector and/or specif compani may time time inconsist view impli inclus sector compani wolf research llc analyst research report model screen wolf research commun client across varieti medium client choos includ email voic blast electron public proprietari websit copyright wolf research llc right reserv materi present document unless specif indic otherwis copyright wolf research llc none materi content copi may alter way transmit distribut parti without prior express written permiss wolf research llc report limit sole use client wolf research author user receiv encrypt decod legisl monitor access wolf research llc content distribut content produc wolf research llc violat understand term relationship
